Hagedoorn P - Search Results

1

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.

Sibum I, Hagedoorn P, Kluitman MPG, Kloezen M, Frijlink HW, Grasmeijer F. Sibum I, et al. Among authors: hagedoorn p. Pharmaceutics. 2019 Dec 25;12(1):24. doi: 10.3390/pharmaceutics12010024. Pharmaceutics. 2019. PMID: 31881695 Free PMC article.

2

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW. Le Brun PP, et al. Among authors: hagedoorn p. Int J Pharm. 1999 Nov 5;189(2):205-14. doi: 10.1016/s0378-5173(99)00251-3. Int J Pharm. 1999. PMID: 10536249

3

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW. Le Brun PP, et al. Among authors: hagedoorn p. Int J Pharm. 1999 Nov 5;189(2):215-25. doi: 10.1016/s0378-5173(99)00252-5. Int J Pharm. 1999. PMID: 10536250

4

Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle.

de Boer AH, Le Brun PP, van der Woude HG, Hagedoorn P, Heijerman HG, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Eur J Pharm Biopharm. 2002 Jul;54(1):17-24. doi: 10.1016/s0939-6411(02)00043-7. Eur J Pharm Biopharm. 2002. PMID: 12084498

5

Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.

de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Int J Pharm. 2002 Dec 5;249(1-2):219-31. doi: 10.1016/s0378-5173(02)00526-4. Int J Pharm. 2002. PMID: 12433450

6

Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols.

de Boer AH, Gjaltema D, Hagedoorn P, Schaller M, Witt W, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Int J Pharm. 2002 Dec 5;249(1-2):233-45. doi: 10.1016/s0378-5173(02)00527-6. Int J Pharm. 2002. PMID: 12433451

7

Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.

de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Int J Pharm. 2003 Jul 24;260(2):187-200. doi: 10.1016/s0378-5173(03)00250-3. Int J Pharm. 2003. PMID: 12842339

8

Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation.

de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Kussendrager KD, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Int J Pharm. 2003 Jul 24;260(2):201-16. doi: 10.1016/s0378-5173(03)00264-3. Int J Pharm. 2003. PMID: 12842340

9

The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.

de Boer AH, Hagedoorn P, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Int J Pharm. 2003 Dec 11;268(1-2):59-69. doi: 10.1016/j.ijpharm.2003.09.004. Int J Pharm. 2003. PMID: 14643977

10

Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.

de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. de Boer AH, et al. Among authors: hagedoorn p. Pharmazie. 2004 Sep;59(9):692-9. Pharmazie. 2004. PMID: 15497751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page